Literature DB >> 24596367

Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review.

Kazunori Hayashi1, Masanari Aono, Kousuke Shintani, Kenichi Kazuki.   

Abstract

BACKGROUND: Intravenous bisphosphonates (BPs) have been used to reduce the frequency of skeletal-related events due to bone metastases of several kinds of cancers. Although many studies on BP-related atypical fractures (BRAFs) due to the use of BP for osteoporosis treatment have been reported, few reports on BRAFs arising as a complication of long-term BP use for bone metastasis of cancer are available. CASE REPORT: A 62-year-old woman with a history of breast cancer presented with right thigh pain after she had a fall. Radiographs indicated a transverse fracture in the shaft of the right femur. She had been on zoledronate treatment for six years. Based on radiographic and histopathological findings, we concluded that the fracture was not a pathological fracture associated with metastasis but was a complication of long-term BP treatment.
CONCLUSION: Clinical oncologists should consider the possibility of BRAFs in patients on long-term zoledronate treatment for bone metastases.

Entities:  

Keywords:  Zoledronate; atypical femoral fracture; bone metastasis; breast cancer

Mesh:

Substances:

Year:  2014        PMID: 24596367

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy.

Authors:  Samantha Peiling Yang; Tae Won B Kim; Patrick J Boland; Azeez Farooki
Journal:  Oncologist       Date:  2017-03-08

2.  The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer.

Authors:  Robert Espey; Stephanie Grimes; Gary Heyburn; William David Kealey
Journal:  BMJ Case Rep       Date:  2017-05-09

3.  Applying low-intensity pulsed ultrasounds (LIPUS) to a zoledronate-associated atypical femoral shaft fracture without cessation of zoledronate therapy for 3 years follow up: a case report.

Authors:  Shoutaro Arakawa; Mitsuru Saito; Makoto Kubota; Hidehiko Suzuki; Shigeki Tsuchida; Kurando Hashimoto; Keishi Marumo
Journal:  Clin Cases Miner Bone Metab       Date:  2015-12-29

Review 4.  American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.

Authors:  Joseph R Geissler; Devendra Bajaj; J Christopher Fritton
Journal:  J Biomech       Date:  2015-02-02       Impact factor: 2.712

5.  Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.

Authors:  Momoko Takahashi; Yukinori Ozaki; Rika Kizawa; Jun Masuda; Kentaro Sakamaki; Keiichi Kinowaki; Taro Umezu; Chihiro Kondoh; Yuko Tanabe; Nobuko Tamura; Yuji Miura; Takashi Shigekawa; Hidetaka Kawabata; Noriyuki Baba; Haruo Iguchi; Toshimi Takano
Journal:  BMC Cancer       Date:  2019-10-22       Impact factor: 4.430

Review 6.  The surgical management and treatment of metastatic lesions in the proximal femur: A mini review.

Authors:  Helin Feng; Jin Wang; Jianfa Xu; Wei Chen; Yingze Zhang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.